We examined the effect of physiological hyperinsulinemia on insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation and phosphatidylinositol (PI) 3-kinase activity in skeletal muscle from six lean-to-moderately obese NIDDM patients and six healthy subjects. A rise in serum insulin levels from ~60 to ~650 pmol/1 increased IRS-1 tyrosine phosphorylation sixfold over basal levels in control muscle (P < 0.01), whereas no significant increase was noted in NIDDM muscle. The reduced IRS-1 phosphorylation in the NIDDM muscle was not related to changes in IRS-1 protein content, since IRS-1 protein expression was similar between control and NIDDM subjects (16.0 ± 1.7 vs. 22.9 ± 4.0 arbitrary units/mg protein for control and NIDDM, respectively; NS). Physiological hyperinsulinemia increased PI 3-kinase activity in control muscle twofold (P < 0.01), whereas no increase in insulin-stimulated PI 3-kinase activity was noted in the NIDDM muscle. Furthermore, in vitro insulin-stimulated (600 pmol/1) 3-0-methylglucose transport was 40% lower in isolated muscle from NIDDM subjects (P < 0.05). The present findings couple both reduced insulin-stimulated IRS-1 tyrosine phosphorylation and PI 3-kinase activity to the impaired insulin-stimulated glucose transport in skeletal muscle from lean-to-moderately obese NIDDM subjects. Diabetes 46:524-527, 1997 I ntense interest has focused on whether the reduced insulin-mediated glucose transport in muscle from NIDDM patients results from alterations in the insulin signal transduction pathway (1-12) or from alterations in the traffic and/or translocation of GLUT4 to the plasma membrane (12-18). Recently, we have shown that an increase in fasting serum insulin levels from -50 to -600 pmol/1 induces a translocation of GLUT4 from an intracellular storage site to the plasma membrane in skeletal muscle from healthy individuals (18, 19 increase in insulin levels did not alter the plasma membrane GLUT4 content in muscle biopsies from NIDDM patients (18), providing evidence for a defect in insulin signaling and/or GLUT4 translocation in muscle from NIDDM patients.
I
ntense interest has focused on whether the reduced insulin-mediated glucose transport in muscle from NIDDM patients results from alterations in the insulin signal transduction pathway (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) or from alterations in the traffic and/or translocation of GLUT4 to the plasma membrane (12) (13) (14) (15) (16) (17) (18) . Recently, we have shown that an increase in fasting serum insulin levels from -50 to -600 pmol/1 induces a translocation of GLUT4 from an intracellular storage site to the plasma membrane in skeletal muscle from healthy individuals (18, 19) . Conversely, a similar increase in insulin levels did not alter the plasma membrane GLUT4 content in muscle biopsies from NIDDM patients (18) , providing evidence for a defect in insulin signaling and/or GLUT4 translocation in muscle from NIDDM patients.
Evidence from animal studies suggests that insulin signaling defects in muscle are associated with altered whole-body glucose homeostasis (2) (3) (4) (5) . In morbidly obese humans (6) and obese rodents (2) (3) (4) (5) , impaired insulin-stimulated glucose transport in skeletal muscle is associated with decreased insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) protein content, decreased IR and IRS-1 phosphorylation, and reduced PI 3-kinase activity. Tumor necrosis factor (TNF)-a has been implicated to play a role in development of insulin resistance in obesity by increasing the serine phosphorylation of IR and IRS-1 (10) . In contrast to the obese state, in hyperglycemic-hypoinsulinemic states, such as in the streptozotocin-induced diabetic rat, IR and IRS-1 phosphorylation and PI 3-kinase activity are enhanced in skeletal muscle (2, 3) , despite reduced insulin-stimulated glucose transport (20) .
Reduced IR phosphorylation has been observed in skeletal muscle from nonobese NIDDM subjects (7) (8) (9) . However, whether skeletal muscle insulin resistance in NIDDM is associated with altered IRS-1 phosphorylation and/or PI 3-kinase activity remains to be established. Thus, we examined the effect of physiological hyperinsulinemia on IRS-1 tyrosine phosphorylation and PI 3-kinase activity in skeletal muscle from NIDDM and healthy subjects.
RESEARCH DESIGN AND METHODS

Subjects.
The study protocol was reviewed and approved by the institutional ethical committee of the Karolinska Institute, and informed consent was received from all subjects before participation. The clinical characteristics of the subjects are presented in Table 1 . Experimental protocol. A modification of the hyperinsulinemic clamp procedure was used in conjunction with an open-muscle biopsy to obtain vastus lateralis muscle (18) . Muscle biopsies were obtained under local anesthesia (mepivacain chloride 5 mg/ml) 30 min after a glucose priming period (basal). Thereafter, a bolus injection of insulin was administered (17.6 nmol • kg" 1 • min" 1 ) for 4 min, and hyperinsulinemia was maintained by means of a continuous insulin infusion (5.5 nmol • kg" 1 • min" 1 ). Forty minutes after the onset of the insulin infusion, a second biopsy (insulin-stimulated) was obtained. Serum insulin levels at the time of the muscle biopsy were 57.0 ± 10.8 and 73.8 ± 26.4 pmol/1 under basal conditions (NS) and 638 ± 44 and 729 ± 90 pmol/1 (NS) under insulin-stimulated conditions for the control and NIDDM subjects, respectively. Each biopsy was obtained from different muscle bundles from the same incision site by means of a Weil-Blakesley conchotome (12) . The muscles were frozen in liquid nitrogen on excision and stored (-80°C) until analysis. Tyrosine phosphorylation and protein expression of IRS-1. Muscle specimens (20 mg) were homogenized in ice-cold buffer as described previously (4) and Data are means ± SE for six subjects in each group. *P < 0.001, fP < 0.01, significantly different from the control subjects. NA, not applicable.
centrifuged at 150,000flt for 35 min (4°C). The supernatant (1 mg) was immunoprecipitated overnight (4°C) with an anti-IRS-1 antibody coupled to protein A-sepharose. The immunoprecipitates were washed as indicated (6), resuspended in Laemmli sample buffer with 100 mmol/1 dithiothreitol, and heated (95°C) for 6 min. The proteins were separated by SDS-PAGE (6% resolving gel), transferred to nitrocellulose membranes, and blocked as described previously (13).
The membranes were incubated with either anti-IRS-1 (total protein expression) or anti-phosphotyrosine (IRS-1 phosphorylation) antibodies. The membranes were washed and incubated with secondary antibodies as previously described (13). IRS-1 was visualized by enhanced chemiluminescence (Amersham, Arlington Heights, IL) and quantified by densitometry. Determination of PI 3-kinase activity in muscle biopsies. Muscle specimens (20 mg) were homogenized in 500 ul lysis buffer, as previously described (6), and solubilized by continuous stirring for 1 h at 4°C. After centrifugation (12, OOO<7 for 4 min), the supernatant (1 mg) was immunoprecipitated overnight (4°C) with either anti-phosphotyrosine antibody (Signal Transduction Laboratories, Lexington, KY) or anti-IRS-1 antibody (gift from Drs. Martin Myers and Morris White) coupled to protein A-sepharose (Sigma, St. Louis, MO). The immune complexes were washed as described (6) and resuspended in 40 ul of buffer (20 mmol/1 HEPES, pH 7.5,180 mmol/1 NaCl). PI 3-Wnase activity was assessed directly on the protein A-sepharose beads as previously reported (5, 11) . The bands corresponding to PI 3-phosphate were quantitated using a Phosphorlmager. Glucose transport measurements in isolated skeletal muscle. Before removal of the "basal" biopsy, an open-muscle biopsy was excised, and isolated muscle strips were prepared for in vitro incubation and assessment of basal and insulin-stimulated (600 pmol/1) 3-O-methylglucose transport as previously described (12) . TNF-a determinations. Fasting TNF-a levels were assessed in serum, using a commercially available kit (Promega, Madison, WI). Human recombinant TNFa was used as a standard. Statistical analysis. Data are presented as means ± SE. Statistical analysis was performed using the unpaired Student's t test. Materials. PI was from Avanti Polar Lipids (Alabaster, AL), and the aluminum backed Silica Gel 60 thin-layer chromatography plates were from EM Separations (Gibbstown, NJ). All other chemicals were purchased from Sigma or Merck (Rahway, NJ). Protein was determined using a kit from Bio-Rad (Richmond, CA).
RESULTS
IRS-1 tyrosine phosphorylation and protein content.
Physiological hyperinsulinemia increased IRS-1 tyrosine phosphorylation approximately sixfold (P < 0.01) in skeletal muscle from the healthy subjects (Fig. 1) . Conversely, insulin infusion did not significantly alter IRS-1 tyrosine phosphorylation in skeletal muscle from NIDDM subjects. Interestingly, basal IRS-1 tyrosine phosphorylation tended to be higher in NIDDM muscle. We next assessed IRS-1 protein expression to determine whether the lack of IRS-1 phosphorylation in NIDDM muscle was associated with altered IRS- Fig.  1 . Skeletal muscle IRS-1 protein expression was similar between control and NIDDM subjects (16.0 ± 1.7 vs. 22.9 ± 4.0 arbitrary units/mg protein forn = 6 control and n = 6 NIDDM subjects, respectively; NS). PI 3-kinase activity. PI 3-kinase was assessed in anti-phosphotyrosine or anti-IRS-1 immunoprecipitates of basal or insulin-stimulated muscle from control and NIDDM subjects (Fig. 2) . Physiological hyperinsulinemia increased tyrosineassociated PI 3-kinase activity twofold (P < 0.01) in the control muscle. Similarly, insulin increased IRS-1-associated PI 3-kinase activity twofold (P < 0.01) in the control muscle. In contrast, insulin failed to increase either tyrosine-or the IRS-1-associated PI 3-kinase activity in NIDDM muscle. Glucose transport. Insulin-stimulated 3-O-methylglucose transport was reduced by 40% in NIDDM skeletal muscle (1.14 ± 0.14 vs. 0.69 ± 0.13 umol • ml" 1 • h" 1 , for control and NIDDM subjects, respectively; P < 0.05). Basal glucose transport was not different between the groups. TNF-a levels. We next assessed serum levels of TNF-a to determine whether the reduced insulin-stimulated IRS-1 tyrosine phosphorylation in NIDDM muscle was related to increased serum TNF-a levels. Fasting TNF-a levels were not significantly different between control and NIDDM subjects (Table 1) .
DISCUSSION
Here we provide the first evidence to show that insulin-stimulated IRS-1 tyrosine phosphorylation and PI 3-kinase activity are reduced in skeletal muscle from lean-to-moderately obese NIDDM subjects. Thus, in addition to reduced IR kinase activity (7) (8) (9) , defects in insulin signaling through IRS-1 and PI 3-kinase may to contribute to impaired glucose transport (6, (14) (15) (16) (17) (18) and reduced plasma membrane GLUT4 content in muscle from NIDDM subjects (16, 18) .
In skeletal muscle from obese rodents and humans, IR kinase activity (3, 4, 6) , IRS-1 tyrosine phosphorylation (2,3), PI 3-kinase activity (3) (4) (5) (6) 11) , and glucose transport (5, 6, 11) are markedly decreased after insulin stimulation. In muscle from morbidly obese humans, these defects are accompanied by decreased expression of several key proteins in the insulin signaling cascade, including the p-subunit of the IR, IRS-1, and the p85 subunit of PI 3-kinase (6) . However in the latter study, the obese subjects had a BMI of -53 kg/m 2 , and consequently, they do not represent the vast majority of the NIDDM population. In the present study, IRS-1 protein content was not significantly altered in skeletal muscle from NIDDM subjects, despite reduced tyrosine phosphorylation. Our results suggest that the decreased IRS-1 tyrosine phosphorylation in muscle from lean-to-moderately obese NIDDM subjects may be a consequence of impaired IR tyrosine kinase activity, whereas defects in muscle from insulinresistant morbidly obese humans may be related to reduced activity and protein expression of IR and IRS-1 (6).
TNF-a has been suggested to induce peripheral insulin resistance in obesity and diabetes by increasing serine phosphorylation of IRS-1, thus converting IRS-1 to an inhibitor of IR through increased serine phosphorylation of the IR (10). Since serum TNF-a levels were not elevated in the NIDDM subjects, elevations in circulatory TNF-a levels are unlikely to account for the reduced insulin-stimulated tyrosine IRS-1 phosphorylation observed in NIDDM muscle. However, TNF-a may be produced locally in skeletal muscle and may function in an autocrine manner to inhibit insulin signaling and glucose transport (21) . Nevertheless, a recent study showed that antibody-mediated neutralization of TNF-a did not improve insulin sensitivity in obese NIDDM subjects (22) . Further studies are warranted to determine the role of TNF-a and insulin signaling in insulinresistant human skeletal muscle. PI 3-kinase associates with tyrosine phosphorylated IRS-1 after insulin stimulation and acts as an important upstream mediator of signaling to p70 S6 kinase, DNA synthesis, and glycogen synthesis (1) . Furthermore, PI 3-kinase has been shown to play a seminal role in insulin-stimulated glucose transport and GLUT4 translocation in skeletal muscle (23) . The present finding couples reduced insulin-stimulated IRS-1 tyrosine phosphorylation and PI 3-kinase activity to the reduced glucose transport observed in NIDDM muscle. Furthermore, the present report is the first to show that physiological hyperinsulinemia is sufficient to activate IRS-1 phosphorylation and PI 3-kinase in vivo in human skeletal muscle.
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